Xilio Therapeutics, Inc. (XLO) Stock

About Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. is led by CEO Rene Russo, employs 64 people, headquartered in US, publicly traded since 2021.

Xilio Therapeutics, Inc. (XLO) stock trades at $7.57 with a market capitalization of $49.81M. The stock is valued at a negative price-to-earnings (P/E) ratio of -6.05, reflecting a net loss over the last twelve months, price-to-book of 2.42, price-to-sales of 0.92. Over the past 52 weeks the stock has ranged between $6.47 and $12.59, and currently trades 39.9% below its 52-week high.

On profitability, Xilio Therapeutics, Inc. generates a return on equity (ROE) of -50.77% (negative, reflecting a net loss), return on capital employed of -26.13%, an operating margin of -95.45%, a net profit margin of -34.06%.

Xilio Therapeutics, Inc. by the numbers, 2019–2025

Between 2019 and 2025 Xilio Therapeutics, Inc. reported revenue of $0 rising to $44.0M. Compounded, revenue has grown —% a year over five years, —% over three, 633.3% over the last twelve months. Net profit fell to $-35.0M.

The most recent net margin is -34.06%. On a trailing twelve-month basis to Jun '26, revenue is $65.0M and net profit $-22.0M.

Borrowings fell from $19.0M to $7.0M, cash from operations was $-5.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged -150.3% over five years, and was -100.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Xilio Therapeutics, Inc. (XLO) — frequently asked questions